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Hedgehog signaling regulates differentia-
tion, survival, and proliferation of the
earliest double-negative (DN) thymocytes,
but its importance at later stages of T-cell
development is controversial. Here we
use loss- and gain-of-function mouse
models to show that Shh, by signaling
directly to the developing thymocyte, is a
negative regulator of pre-TCR–induced
differentiation from DN to double-positive
(DP) cell. When hedgehog signaling was
reduced, in the Shh/ and Gli2/ thy-
mus, or by T lineage–specific transgenic
expression of a transcriptional-repressor
form of Gli2 (Gli2C2), differentiation to
DP cell after pre-TCR signal transduction
was increased. In contrast, when Hh sig-
naling was constitutively activated in thy-
mocytes, by transgenic expression of a
constitutive transcriptional-activator form
of Gli2 (Gli2N2), the production of DP
cells was decreased. Gene expression
profiling showed that physiologic Hh sig-
naling in thymocytes maintains expres-
sion of the transcription factor FoxA2 on
pre-TCR signal transduction. (Blood.
2009;113:5144-5156)
Introduction
The thymus provides a specialized environment that supports the
maturation of lymphocyte precursors into functional T cells, and
one factor from the thymic epithelium that signals to developing
thymocytes is the secreted intercellular signaling protein Sonic
hedgehog (Shh).1 Shh, one of 3 mammalian hedgehog (Hh)
proteins, is a morphogen essential for embryogenesis,2-4 and
homeostasis of adult tissues.5,6 The mammalian Hh proteins trigger
a common signaling pathway: They bind their cell-surface receptor
Patched, which on Hh interaction releases the Hh-signal transduc-
tion molecule Smoothened (Smo) from inhibition, and Smo
activates members of the Gli family of transcription factors, Gli1,
Gli2, and Gli3.3,7,8 The Gli proteins bind DNA in a sequence-
specific manner and have specialized functions and distinct tempo-
ral and spatial expression patterns.9,10 On Hh signal transduction,
they are transported to the nucleus to promote target-gene transcrip-
tion. Gli1 acts only as a transcriptional activator and is not essential
for mouse development.11 Gli2 and Gli3 can be processed to
function as transcriptional activators or transcriptional repres-
sors.12,13 In the absence of Hh signaling, Gli2 and Gli3 undergo
modification by phosphorylation and cleavage of their C-terminal
transactivation domain to function as transcriptional repressors.9,10
Gli2 and Gli3 are essential for mouse development and have
distinct, and partially overlapping, functions.14 Although Gli2 and
Gli3 are bifunctional, Gli2 acts in vivo primarily as a transcrip-
tional activator and is necessary to initiate the first transcriptional
changes on Hh signal transduction,15 whereas Gli3 functions
mainly as a negative regulator of transcription.15,16
During T-cell development, thymocytes pass through develop-
mental stages defined by expression of cell-surface markers.
CD4CD8 double-negative (DN) thymocytes differentiate into
CD4CD8 double-positive (DP) thymocytes, which then mature
into CD4 or CD8 single-positive cells. The DN population can
be further subdivided: the most immature population expresses
CD44 but not CD25 (DN1). As these thymocytes mature they gain
CD25 expression (DN2), then lose CD44 expression (DN3),
eventually becoming negative for both CD44 and CD25 (DN4)
before differentiating into DP, often via an immature CD8
intermediate (CD8ISP).
During the DN3 stage, the TCR chain locus is rearranged. Cells
that successfully rearrange a TCR allele and express a functional
TCR chain signal through the pre-TCR, causing rearrangement of the
other TCR locus to be suppressed (allelic exclusion), rescue from
apoptosis, proliferation. and up-regulation of CD4 and CD8 expression.
This process, known collectively as -selection, is necessary for the
transition from DN to DP thymocyte.17
In the mouse thymus, Shh is expressed by some epithelial cells
in the subcapsular region, medulla, and corticomedullary junction,
and the molecules that allow a cell to respond to Shh are expressed
by both lymphoid and stromal components.1,6,18-23 Analysis of mice
mutant for Shh, Gli3, and Smo have shown that Hh signaling is
necessary for efficient survival, proliferation, and differentiation of
thymocytes at the transition from DN1 to DN2,18,21,22 but the role of
Hh signaling at the transition from DN to DP thymocytes is
controversial. Different experimental approaches have produced
conflicting results that have led to 3 different interpretations: that
Hh is a negative regulator of the pre-TCR signal and differentiation
to DP6,21,24; that Shh is a positive regulator of the DN to DP
transition18; or that Hh signaling does not influence thymocyte
differentiation after the DN2 stage.22
In vitro studies first demonstrated that Hh signaling influences
thymocyte development6,24 and suggested that Hh signaling was a
negative regulator of differentiation to DP cell. Treatment of mouse
fetal thymus organ cultures (FTOCs) with recombinant Shh protein
arrested thymocyte development at the DN3 stage after TCR
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chain rearrangement, whereas neutralization of endogenous Hh
signaling by anti-Hh antibody treatment increased DP produc-
tion.6,18 In addition, in anti-CD3–treated Rag1/ FTOCs, differen-
tiation to DP was arrested or enhanced by Shh or anti-Hh treatment,
respectively.6
In contrast to these in vitro experiments, ex vivo analysis of
Shh/ fetal thymi on E16.5 suggested that Shh promotes differen-
tiation to the DP stage,18 as both thymus size and the proportion of
DP cells were greatly reduced. Analysis of Gli3 mutants showed
that regulation of Hh signaling after pre-TCR signal transduction,
via Gli3, is necessary for efficient transition from DN to DP.21
Depending on whether Gli3 is acting as an activator or repressor,
the latter data support either a positive or negative role, respec-
tively, for Hh signaling after pre-TCR signal transduction.
Finally, consistent with no role for Hh at the transition to DP
cell, analysis of a conditional T lineage–specific Smo knockout
model failed to reveal an influence of Hh after the DN2 stage.22
Lck-Cre–induced deletion of Smo reduced both the number and
relative proportion of DP cells in the adult, but this reduction in DP
cells was interpreted as the result of the earlier effects observed on
the DN1 and DN2 populations, rather than an effect on or after
pre-TCR signaling. In addition, in vivo anti-CD3–induced differen-
tiation of Rag1/ thymocytes produced similar numbers of DP
cells, in both conditional Smo-deficient mice and littermates.22
These conflicting interpretations could reflect functional differ-
ences in the experimental models used, such as differences between
the adult and fetal thymus, or in the case of the Shh/, systemic
effects of the mutation on the developing embryo. Alternatively, the
action of Hh signaling on differentiation to DP could be indirect
through another cell type (eg, epithelium), so that when T lineage–
specific mutants, such as the conditional Smo knockout, were
analyzed no effect was observed. To reconcile all experimental
data, we have proposed a model in which Shh promotes thymocyte
differentiation before pre-TCR signaling, but negatively regulates
differentiation to DP after pre-TCR signal transduction.1
Here, to resolve this controversy and provide further experimen-
tal evidence, we re-examine the transition from DN to DP in novel
fetal and adult mouse models. By differentiating between events
before and after pre-TCR signal transduction, we show that Shh, by
signaling directly to the developing thymocyte, is a negative
regulator of pre-TCR–induced differentiation to DP cell.
Methods
Mice
Gli2/ mice14 and Shh/ mice25 were on C57BL/6 background. lck-
Gli2N2 and lck-Gli2C2 transgenic mice were as described.20,26 For
hydrocortisone (HC) treatment, mice were injected intraperitoneally with
0.03 mg per gram of body weight HC (Sigma-Aldrich, St Louis, MO) in
PB, and analyzed after 2 to 7 days.27 The United Kingdom Home Office
(London, United Kingdom) approved mouse studies.
PCR analysis
DNA was extracted from tissue by digesting in lysis buffer containing
50 mM KCl, 1.5 mM MgCL2, 10 mM Tris HCL (pH 8.5), 0.01% gelatin,
0.45% Nonidet P-40, 0.45% Tween20, and 0.5 g/mL proteinaseK in water.
Approximately 1 g DNA was used per polymerase chain reaction (PCR).
Primers for Gli2 gene14 were oGli2 (Gli2WT) (5)AAACAAAGCTCCTGT-
CACG, (3)CACCCCAAAGCATGTGTTTT, OpPNT (Gli2mutated)
(5)CACCCCAAAGCATGTGTTTT, (3)ATGCCTGCTCTTTACTGAAG.
Analysis of TCR gene rearrangement by quantitative PCR (Q-PCR),
using 5 primers to V8.2 and V5.1 and a 3 primer to J2.7, was as
described.28
Cell sorting
DN1-4 populations were sorted, using anti-CD25FITC, -CD4/8PE, and
-CD44Cychrome. Staining with anti-CD4PE and -CD8Cychrome allowed sorting
of DP and SPs, on MoFlo (Cytomation, Fort Collins, CO).
QRT-PCR for Gli2 RNA expression
RNA was extracted using Absolutely-RNA Miniprep kit (Stratagene, La
Jolla, CA) from fluorescence-activated cell sorting (FACS)–sorted cells.
cDNA was synthesized using Superscript-II (Invitrogen, Carlsbad, CA).
Quantitative reverse-transcription (QRT)–PCR was as described,21 using
primers Gli2F AGAACCTGAAGACACACCTGCG, Gli2R GAGGCAT-
TGGAGAAGGCTTTG.
Antibodies and flow cytometry
Cells were stained as described21 using directly conjugated antibodies from
BD PharMingen (San Diego, CA) and analyzed on a FACScan (BD
Biosciences). Live cells were gated by FSC/SSC profiles. Data represent
more than 3 experiments.
Intracellular staining for TCR27 and phospho-Erk29 were as described.
FTOC
FTOC was as described6 with azide-free anti-CD3 monoclonal antibody
(mab) treatment where stated.
PCR arrays with anti-CD3–treated Rag1/ and Gli2C2Rag1/
thymocytes
One lobe of each thymus was cultured overnight in AIM-V medium with
5 g/mL anti-CD3. Thymocytes were extracted from the second, non-
treated, control lobe. Thy1.2 cells were separated using the EasySep
system (StemCell Technologies, Vancouver, BC), following the manufactur-
er’s instructions. RNA was extracted using Absolutely-RNA kit (Strat-
agene) following the manufacturer’s instructions.
Approximately 250 ng RNA was used for cDNA synthesis using the
RT2 First strand kit (SuperArray Bioscience, Frederick, MD) following the
manufacturer’s instructions. cDNA synthesized was used for Mouse Signal
Transduction PathwayFinder RT2 Profiler PCR Array (SA Biosciences,
Frederick, MD). Three arrays were performed with preparations from each
of Rag1/, Gli2C2Rag1/, Rag1/  anti-CD3–treated, and
Gli2C2Rag1/  anti-CD3–treated thymocyte samples. Ct values for
each gene were obtained by subtracting the mean threshold cycle (Ct) of the
housekeeping genes (Gusb, HPRT, Hsp90ab1, and Actb) from the Ct value
of the gene. Average Ct value for 3 experiments was calculated, for each
gene, and average normalized transcription was calculated as follows:
2averageCt. Fold up- or down-regulation of transcription after anti-CD3
treatment was calculated by dividing the average normalized transcription
of each gene in the test samples (Rag1/  anti-CD3 or Gli2C2Rag1/ 
anti-CD3) by the corresponding control (Rag1/ or Gli2C2Rag1/)
value. Statistical significance in up- or down-regulation of transcription was
determined by Student t test (paired, 2-tailed), comparing the Ct values,
for each gene, before and after treatment from the 3 experiments performed
for Rag1/ or Gli2C2Rag1/ genotypes. To determine significant
differences in the response in anti-CD3 treatment between Rag1/ and
Gli2C2Rag1/ thymocytes, we performed Student t test (2-sample, equal
variance, 2-tailed distribution) for each gene comparing the Ct
(Ct  Ct
anti-CD3 treated  Ctcontrol) values from the 3 experiments.
Significant differences were identified when P was less than .05.
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Results
Gli2 is expressed differentially in fetal DN subsets
Gli2 is essential to initiate the Hh signal and activate transcription
of target genes.15 Therefore, to investigate the function of Hh
pathway activation in developing DN cells, we followed thymocyte
development in Gli2/ embryos on sequential embryonic days.
Gli2-deficient embryos die just before birth, and in contrast to
Shh/ embryos,25 are of fairly normal size and appearance,14 so
effects on thymocyte development are unlikely to be due to
systemic differences in embryo growth or survival.
We analyzed the expression pattern of Gli2 in developing fetal
thymocyte populations. Components of the Hh signaling pathway,
including the Gli proteins, are differentially expressed in adult
thymocyte populations.6,19-22 In the fetal thymus, Gli3 is differen-
tially expressed in DN cells, with expression in the DN1 popula-
tion, down-regulation in the subsequent DN2 and DN3 stages, and
highest expression in the DN4 population.21
Thymocyte populations were FACS-sorted from E16.5 fetal
thymi and transcription of Gli2 was analyzed by QRT-PCR (Figure
1A). Gli2 was most highly expressed in DN1 and DN2 cells,
down-regulated at the DN3 stage, and up-regulated more than
3-fold in the DN4 population. This expression pattern suggests that
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Figure 1. Gli2 expression in thymocytes on E16.5, and function in E13.5 and E14.5 thymus. (A) Gli2 expression in sorted C57BL/6 E16.5 thymocytes. Error bars
represent SD. (B) Gli2 affects the transition from DN1 to DN2 in E13.5 embryos (WT, n  5; Gli2/, n  12; Gli2/, n  8). Relative number of thymocytes on E13.5. To allow
comparison between litters, the number of cells in each thymus was divided by the mean of WT littermates to give a relative cell number for each thymus. Dot plots show DN
subset composition of E13.5 thymi. Cells were gated for CD45.2, and analyzed by CD25 and CD44 expression. Bar chart shows the relative percentage of DN1 cells in E13.5
thymi. The difference between WT and Gli2/ is statistically significant (P  .02). (C) Thymocyte development in E14.5 Gli2/ and littermate embryos (WT, n  17; Gli2/,
n  27; Gli2/, n  15). Bar chart shows the relative thymocyte number on E14.5. The difference between WT and Gli2/ is significant (P  .04). Top dot plot shows E14.5
thymocytes stained with anti-CD45.2. Cells positive for CD45.2 were analyzed for CD25 and CD44 expression. Righthand bar charts show the relative percentage of DN1 and
DN3 cells in E14.5 thymi. Differences in mean relative percentages of DN1 and DN3 populations were statistically significant between WT and Gli2/ (P  .04 and P  .002,
respectively). Histograms show Draq5 staining of E14.5 thymocytes. The percentage of cells in G2S/M is given.
5146 ROWBOTHAM et al BLOOD, 21 MAY 2009  VOLUME 113, NUMBER 21
For personal use only.on August 22, 2019. by guest  www.bloodjournal.orgFrom 
Gli2 is likely to function early in thymocyte development at
DN1/DN2 (as has been shown for Shh, Gli3, and Smo18,21,22) and in
the DN4 population. We therefore assessed the impact of Gli2
mutation on these 2 developmental stages by analyzing thymocyte
development from E13.5 to just before birth.
Inefficient differentiation from DN1 to DN2 in Gli2/ thymus
In embryos, thymocyte development occurs in a more or less
synchronized wave facilitating analysis of specific stages of
development on different embryonic days, and on E13.5 the
majority of cells are DN1 and DN2 (Figure 1B). On E13.5, the
difference in cell number between Gli2/ and WT littermate thymi
was not significant (Figure 1B), but the proportion of DN1 cells
was significantly increased (P  .02) in the Gli2/ compared with
WT (Figure 1B), and the proportion of DN2 cells was concomi-
tantly decreased. There were no differences in anti-ckit or anti-
B220 staining on the CD45CD44 population between WT and
Gli2/ (data not shown).
We assessed thymocyte development on E14.5, to ask whether
the inefficient DN1 to DN2 transition observed on E13.5 impacted
on subsequent developmental stages. On E14.5, thymocyte number
was significantly reduced, and in addition to the increase in the
DN1 population, the proportion of DN3 cells was significantly
reduced, indicative of a developmental delay (Figure 1C). There
was no significant difference in the proportion of thymocytes in
G2S/M as assessed by Draq5 staining (Figure 1C).
On E15.5 there was no significant difference in cell number, or
in the proportions of DN3 or DN4 cells (Figure 2A). To test for
TCR expression, we measured intracellular TCR (icTCR)
protein in DN populations. In the DN3 population, the proportion
of icTCR was similar for both the Gli2/ and WT littermates,
typically around 13% (Figure 2B). In contrast, the proportion of
icTCR cells was reduced in the Gli2/DN4 population com-
pared with WT (Figure 2B). During fetal thymocyte development,
TCR expression is not necessary for transition from DN3 to DN4
and the majority of the DN4 population do not express icTCR
until E17.5.27 We therefore measured TCR gene rearrangement
using a Q-PCR assay,28 using 5 primers to V8.2 and V5.1 and a
3 primer to J2.7 (Figure 2C). We did not detect a statistically
significant reduction in either V8.2 to J2.7 or V5.1 to J2.7
rearrangement in the Gli2/ DN cells, relative to WT, suggesting
that the reduction in icTCR staining in the DN4 population was
most likely the consequence of delayed progression of thymocyte
development.
Reduced transition from DN to DP in E16.5 Gli2/ mice
DP cells first appear on E16.5, so to assess the impact of Gli2
mutation on differentiation to DP we analyzed E16.5 Gli2/
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Figure 2. Gli2 function in the E15.5 thymus. (A) Phenotype of E15.5 Gli2/ thymi (WT, n  8; Gli2/, n  9; Gli2/, n  7). Bar chart shows the relative number of
thymocytes on E15.5; error bars are SD. The difference between WT and Gli2/ was not statistically significant. Dot plot shows the relative proportions of DN3 and DN4
populations: Cells negative for CD3, CD4, CD8, and CD44 were analyzed for CD25 expression. Cells positive for CD25 (DN3) and negative for CD25 (DN4) were gated
separately. There were no significant differences in the proportion of DN3 and DN4 cells on E15.5. (B) Intracellular TCR (icTCR) expression in the E15.5 WT and Gli2/
thymus. Histogram plots of icTCR staining gated on DN3 (left) and DN4 (right) cells. Bar chart shows the relative percentage of icTCR on DN4 cells in E15.5 thymi. The
difference between WT and Gli2/ was statistically significant (P  .02). (C) Bar charts to show degree of V8 to J2.7 (left chart) and V5 to J2.7 (right chart)
rearrangement in E15.5 WT and Gli2/ thymocytes, assessed by Q-PCR.
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thymi. There was no significant difference in thymocyte number on
E16.5 between the Gli2/ and WT littermates, but the proportions
of DP and ISP cells were significantly reduced (Figure 3A), and the
DN population was increased.
We also found a reduction in the developmentally regulated
marker CD2.30,31 In Gli2/ thymocytes, cell-surface expression of
CD2 was reduced from 28.3% in WT to 7.8%. This reduction did
not simply reflect the decrease in DP cells, as when we gated on the
DN population CD2 expression was reduced from 14.4% to 3.2%
(Figure 3A).
Given that we were unable to detect a difference in cell-cycle
status between Gli2/ and WT in the DN populations (Figure 1C),
but the number of DP and ISP cells was reduced relative to WT in
the E16.5 Gli2/ thymus, we asked whether Gli2 is necessary for
efficient survival of DN, ISP, or DP populations. We assessed
apoptosis by annexin V staining in DN1, CD25DN, DN4, CD8ISP,
and DP populations on E16.5 (Figure 3B). We found no significant
differences in the mean percentages of annexin V cells between
E16.5 WT, Gli2/, and Gli2/ littermates in any thymocyte
population. This is in contrast to the Shh/ thymus, in which
apoptosis is increased relative to WT in the E16.5 DN4 popula-
tion,18 and suggests that the functions of Gli2 downstream of Shh
signaling in thymocytes are partially redundant with Gli1 or Gli3,
as has been shown in other tissues.14
Accelerated differentiation to DP population after pre-TCR
signaling
As we found that Gli2 was not necessary for thymocyte survival
(Figure 3B), it seemed likely that the reduction in the DP
population observed on E16.5 was a consequence of an earlier
requirement of Gli2 (and Hh signaling). We therefore asked
whether the DP population could recover. On E17.5 there were
approximately 2.5 times more DP thymocytes in the Gli2/
thymus than in WT (P  .025; Figure 3C), indicating that after
pre-TCR signal transduction, Gli2/ thymocytes expand and
differentiate more quickly than their WT counterparts.
From E13.5 to E16.5 the Gli2/ thymus was on average
slightly smaller than that of WT littermates, but by E17.5 it rapidly
expanded to contain 2.5-times more thymocytes than WT, and
remained on average larger on E18.5 (Figure 3D). The expansion of
the Gli2 deficient thymus corresponded to the day of embryonic
development on which icTCR chain expression in the DN
populations was approaching adult levels27 and capable of pre-TCR
signal transduction. This presumably could not be detected on
E16.5, because of low pre-TCR complex expression27 and the
earlier developmental delay. These data indicate that Hh signaling,
via Gli2, is a negative regulator of thymocyte expansion and
differentiation to DP cell, after pre-TCR signal transduction, during
fetal development (Figure 3D).
Hh pathway activation impedes reconstitution of the DP pool in
adult mice
Analysis of T-lineage–specific Smo conditional knockout mice has
not revealed an influence of Hh signaling at the transition from DN
to DP in the adult thymus,22 but this ex vivo analysis of Gli2/
embryonic thymus and previous in vitro experiments using fetal
thymus have indicated that Hh signaling is a negative regulator of
the transition.6,21,24 Differences in the molecular regulation of
thymocyte development between adult and fetus might account for
this discrepancy. We therefore investigated the impact of Hh
signaling on the production of DP cells in the adult thymus.
Gli2-deficient embryos die before birth,14 so we used mouse
models in which Hh signaling is specifically repressed or activated
in T-lineage cells, by transgenic expression of activator-only or
repressor-only truncated forms of Gli2, under the control of the lck
promotor.13,20,26,32 Our earlier work showed that these transgenics
were successful at up-regulating (Gli2N2 [constitutively active
Hh signal]) or down-regulating (Gli2C2 [constitutive repressor of
Hh signaling]) Hh target genes in T-lineage cells. However, our
previous studies of the Gli2N2 and Gli2C2 thymi had focused on
later stages of T-cell development, and relative differences in the
proportion of the DP population were small and were effected by
changes at the DP to SP transition.20,26
Therefore, to examine differentiation from DN to DP in a
synchronized wave, we used treatment with hydrocortisone (HC) to
deplete the adult thymus by inducing apoptosis in all but the most
mature cells.27 We then followed the recovery of the DP population,
as the thymus grows to recover its normal size and subset
distribution during the week after treatment. This strategy has
previously been used to analyze the developmental sequence and
timing of transition between thymocyte populations,27,33 allowing
analysis of adult thymocyte differentiation in a synchronized wave,
without resorting to the production of radiation chimeras. It
facilitated detection of differences in the rate of differentiation to
DP, which in adult mice is complicated by the fact that the adult
thymus has reached steady state, so the transition is no longer
synchronized, and there are pre-existing cells at all stages of
development and homeostasis between populations. Adult Gli2N2,
Gli2C2, and their respective WT littermates were injected with
HC and analyzed after 2 to 6 days (Figure 4).
In the case of the Gli2N2 experiment, the DP population was
depleted in both Gli2N2 and WT littermates, to approximately 4%
DP, with 7% to 8% DN, 2 days after HC treatment (Figure 4A). The
Gli2N2 thymi then produced DP cells at a slower rate than those
of their WT littermates. Four days after HC treatment, the Gli2N2
thymus contained 16.1% DP cells compared with 31.4% DP cells in
the WT. After 5 days, production of DP cells in the Gli2N2
transgenic was still significantly impeded (P  .01) with the WT
Figure 3. Reduced transition from DN to DP in E16.5 Gli2/ mice. (A) Thymocyte development on E16.5 (WT, n  7; Gli2/, n  15; Gli2/, n  7). Left bar chart shows
relative number of thymocytes on E16.5. Error bars show SE. The difference between WT and Gli2/ was not statistically significant. Dot plots show anti-CD4 and anti-CD8
staining on E16.5 thymocytes. Right bar chart shows the relative percentage of DP cells in E16.5 thymi. The difference between WT and Gli2/ was statistically significant
(P  .007). Histograms show CD2 expression in E16.5 thymi. Left panels: CD2 expression on all thymocytes. Right panels: CD2 expression on DN cells. The difference in
percentage of CD2 cells overall and on DN cells between Gli2/ and Gli2/ thymi were statistically significant (P  .01 and P  .04, respectively). (B) Apoptosis in
thymocyte populations on E16.5, measured by annexin V staining. Scatterplots show the percentage of annexin V cells in DN1, CD25DN, DN4, CD8ISP, and DP thymocyte
populations in WT (n  4),/ (n  8), and/ (n  4) embryos. Mean percentage positive was: DN1 WT, 1.85;/, 2.29;/, 2.62. CD25DN WT, 1.55;/, 1.79;/,
2.0. DN4 WT, 0.57; /, 0.78; /, 0.72. CD8ISP WT, 2.10; /, 2.19; /, 2.75. DP WT, 1.01; /, 1.21; /, 1.32. There were no significant differences in the mean
number of annexin V cells between genotype of mice in any thymocyte population. (C) Thymocyte development on E17.5 (WT, n  7; Gli2/, n  4; Gli2/, n  7). Relative
thymocyte number on E17.5. The difference between WT and Gli2/ was statistically significant (P  .02). Dot plots show anti-CD4 and anti-CD8 staining for E17.5
thymocytes. (D) Relative thymocyte number from E13.5 to E18.5, normalized to mean WT littermate value of 1.0. (For E18.5: WT, n  5; Gli2/, n  5; Gli2/, n  5.) Error
bars show SD.
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Figure 4. Thymocyte recovery after hydrocortisone treatment in Gli2N2 and Gli2C2 transgenic mice. (A) Dot plots show anti-CD4 and anti-CD8 staining for Gli2N2
transgenic thymocytes and WT littermate thymocytes 2 to 6 days after treatment with HC. Bar chart shows the mean relative proportion of DP cells 5 days after HC treatment for
WT and Gli2N2 transgenic mice. The difference in mean percentage of DP cells was statistically significant (P  .01). (B) Dot plots show anti-CD4 and anti-CD8 staining for
Gli2C2 transgenic thymocytes and WT littermate thymocytes 2 to 5 days after HC treatment. Bar chart shows the mean relative proportion of DP cells 4 days after HC
treatment. The difference in DP percentage was statistically significant (P  .004). (C) Graph of relative kinetics of DP recovery after HC treatment in WT, Gli2N2, and
Gli2C2. Error bars represent SD. (Day 2: WT, n  6; Gli2N2, n  3; Gli2C2, n  3. Day 4: WT, n  7; Gli2N2, n  3; Gli2C2, n  3. Day 5: WT, n  7; Gli2N2, n  3;
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DP population recovering to around 75.7%, compared with 53.7%
in the Gli2N2 transgenic (Figure 4A).
In contrast, the Gli2C2 transgenic thymi produced DP cells more
quickly than WT. In a typical experiment, the DP population was
depleted 2 days after HC treatment, but after 4 days 64% of Gli2C2
thymocytes were DP cells, compared with 6% of WT (P .004; Figure
4B).After 5 days, the Gli2C2 thymus contained a normal proportion of
DP cells, compared with 58.5% in the WT (Figure 4B).
Six days after HC treatment, the DP populations in all geno-
types of mice in all experiments had recovered to around 80%
(Figure 4C). The relative kinetics of DP reconstitution after HC
treatment (Figure 4C) demonstrated that whereas constitutive
activation of Hh signaling (Gli2N2) impeded differentiation to
DP, repression of Hh signaling in thymocytes (Gli2C2) enhanced
DP cell production, in the adult thymus in vivo.
Hh signaling is a negative regulator of pre-TCR signal,
reducing ERK phosphorylation
Our data indicate that the Hh signaling pathway is a negative
regulator of the transition from DN to DP in vivo in both the fetal
and adult thymus. As pre-TCR signal transduction is essential for
this stage of development, we used Rag1/ E15.5 FTOC in which
anti-CD3 mab treatment mimics the pre-TCR signal,34,35 to investi-
gate the impact of Hh signaling on pre-TCR signal transduction.
We treated Shh/Rag1/ and Rag1/ littermate FTOC with
anti-CD3 and analyzed differentiation to DP after 3 days. Consis-
tent with the phenotype of E13.5 Shh/Rag/ embryos,18 before
culture the Shh/Rag1/ thymi were smaller and contained a
greater proportion of DN1 cells than Rag1/ littermate thymi
(Figure 5A). Propidium iodide staining showed that fewer thymo-
cytes were in SG2/M in the Shh/Rag1/ (12.7%) than in
Rag1/ (20.3%) littermate thymus (Figure 5B). After anti-CD3
treatment, the Shh/Rag1/ thymocytes expanded and differenti-
ated to DP faster than the anti-CD3–treated control Rag1/
thymocytes (Figure 5C). The proportion of DP cells was increased
from 16.1% in the Rag1/ FTOC to 25.3% in the Shh/Rag1/
FTOC. As expected, anti-CD3 treatment stimulated proliferation,
and the proportion of thymocytes in SG2/M was increased to
30.8% in the anti-CD3–treated Shh/Rag1/ FTOC and 27.3%
in the anti-CD3–treated Rag1/ littermate FTOC. To test whether
Gli2 functions downstream of Shh at this stage of thymocyte
development, we also compared differentiation to DP cell in
anti-CD3–treated Gli2/Rag1/ FTOC and littermate Rag1/
FTOC. The anti-CD3–treated Gli2/Rag1/ FTOC differentiated
more quickly than their Rag1/ littermate counterparts, and
in a typical experiment, 28.9% of thymocytes were DP in the
Gli2/Rag1/ FTOC, compared with 16.4% in littermate Rag1/
FTOC (Figure 5D), confirming that Gli2 is downstream of Shh as a
negative regulator of differentiation and that it functions as an
activator of transcription at this developmental stage.
The accelerated differentiation to DP in the anti-CD3–treated
Shh/Rag1/ FTOC appeared to contrast with the phenotype of
the E16.5 Shh/ thymus, which like the E16.5 Gli2/ thymus,
contained fewer DP cells than WT.18 It demonstrates that Shh is a
negative regulator of pre-TCR–induced differentiation to DP, and
therefore indicates that in the E16.5 Shh/ thymus, as seen in the
E16.5 Gli2/ thymus, the reduction in DP cells was the result of an
earlier effect on thymocyte development.
Given that T lineage–specific conditional deletion of Smo from
Rag-deficient thymocytes has been previously shown to have no effect
on differentiation to DP on anti-CD3 treatment,22 it was possible that the
effect of Shh deletion on thymocyte differentiation was indirect via
another cell type, and not the result of reduction of Hh pathway
activation in developing thymocytes. To test this, we treated FTOC from
Gli2N2Rag1/ or Gli2C2Rag1/ embryos and their respective
Rag1/ littermates for 3 days with anti-CD3, to follow the differentia-
tion of thymocytes in which Hh signal transduction was either specifi-
cally activated or specifically repressed.
In the case of the Gli2N2Rag1/ FTOC, where Hh signaling
is constitutively active in thymocytes, after treatment with anti-
CD3 both thymocyte number and pre-TCR–induced differentiation
to DP cell were significantly reduced compared with Rag1/
littermates (Figure 6A). In the Gli2N2Rag1/ FTOC, 7.2% of
thymocytes were DP compared with 23.3% in the Rag1/ control
FTOC (Figure 6A). This reduction in anti-CD3–induced differentia-
tion showed that Hh pathway activation inhibited pre-TCR signal-
ing in a thymocyte-autonomous manner.
We measured MAPKinase pathway activation on pre-TCR signal
transduction, using a FACS-based assay29 to compare icERK phosphor-
ylation between Gli2N2Rag1/ and Rag1/ thymocytes stimulated
with anti-CD3 (Figure 6B). On pre-TCR stimulation, there was a clear
shift in icphospho-ERK levels in the Rag1/ thymocytes, with an
approximately 2-fold increase in mean fluorescence intensity. In con-
trast, the shift in anti–icphospho-ERK fluorescence was negligible in the
Gli2N2Rag1/ thymocytes (Figure 6B) on pre-TCR stimulation.
Thymocyte-specific repression of Hh signaling in the
Gli2C2Rag1/ FTOC had the opposite effect on pre-TCR–
induced differentiation to DP, and promoted the transition. The
proportion of DP cells in the anti-CD3–treated Gli2C2Rag1/
FTOC was increased to 39.4%, compared with 28.1% in the control
anti-CD3–treated Rag1/ FTOC (Figure 6C), but there was no
significant difference in thymocyte number between the 2 geno-
types of FTOC (Figure 6D). As expected from the Gli2N2Rag1/
experiment, icERK phosphorylation was increased on pre-TCR
stimulation of Gli2C2Rag1/ thymocytes compared with Rag1/
littermate thymocytes (Figure 6E).
Thus, the fact that constitutive repression or activation of Hh
signaling in thymocytes has opposing effects on pre-TCR–induced
differentiation to DP confirms that Hh signaling is a direct negative
regulator of pre-TCR–induced differentiation via the MAPkinase cascade.
Identification of transcriptional targets of pre-TCR signal
transduction
To identify genes that are transcriptionally targeted on pre-TCR
signal transduction under physiologic conditions, or on repression
of Hh signaling, we used a QRT-PCR array approach to profile the
expression of 84 genes representative of different signal transduc-
tion pathways. RNA was prepared from control and anti-CD3–
treated thymocytes purified from Gli2C2Rag1/ and Rag1/
littermate thymi for QRT-PCR analysis. We repeated this experi-
ment 3 times, with independent groups of littermate mice, and
identified genes whose transcription was significantly altered by
pre-TCR signal transduction (Figure 7). This strategy identified 6
genes that were up-regulated on anti-CD3 treatment, and that were
not differentially regulated between Gli2C2Rag1/ and Rag1/
thymocytes: the TCR signal modulator CD5, the transcription
factor Tcf7, the EGR1-binding protein, Nab2, the antiapoptotic
factor Birc3, Fas ligand, and the transcriptional regulator Nrip1
(Figure 7A). The identification of CD5 and Tcf7 thus validated the
experimental approach, as cell-surface CD5 is known to be
up-regulated on pre-TCR signal transduction36 and Tcf7 expression
is increased on pre-TCR signaling.37 The up-regulation of the
EGR1-binding protein, Nab2, is of interest, given that EGR1
promotes thymocyte development at -selection.38,39
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We also identified 9 genes that were significantly down-regulated on
anti-CD3 treatment, and that were not differentially regulated between
Gli2C2Rag1/ and Rag1/ thymocytes (Figure 7B). These included
CD25, TRp53 (p53), Wnt-1, and Brca1. Down-regulation of CD25 is an
early phenotypic change on pre-TCR signal transduction, and therefore
serves as an internal control for detection of transcriptional down-
regulation. Likewise consistent with its down-regulation on pre-TCR
signal transduction, p53 deficiency allows Rag-deficient thymocytes to
differentiate to DP.40 Both Brca1 and Wnt-1 are necessary for thymocyte
development and proliferation41,42 but their transcriptional regulation
has not previously been linked to pre-TCR signal transduction or the
transition from DN to DP. We also found down-regulation of Myc,
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Telomerase reverse transcriptase (Tert; itself a transcriptional target of
Myc), the antiapoptotic factor Birc1a, Cadherin 1, and HoxA1.
Hh signaling maintains FoxA2 expression on pre-TCR signal
transduction
We then looked for genes that were differentially regulated by
the pre-TCR on repression of Hh signaling compared with WT,
and interestingly identified only one significant transcriptional
difference: FoxA2 (P  .04; Figure 7C). There were no sig-
nificant differences in gene expression between Rag1/ and
Gli2C2Rag1/ thymocytes before anti-CD3 treatment, indicat-
ing that the difference in transcription of FoxA2 was a conse-
quence of pre-TCR signal transduction. On anti-CD3 treatment,
there was a 6-fold down-regulation of the transcription factor
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anti-CD3 mab cross-linked with biotinylated anti–hamster IgG for 2 minutes; and Gli2N2Rag1/, n  3) thymocytes, normalized to that of their Rag1/ littermate controls.
Error bars show SE.
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FoxA2 in the Gli2C2Rag1/ only. FoxA2 is essential for
mouse development and FoxA2/ embryos die at E10 with
defects in node, notochord, neural tube, and gut.43,44 In the
mouse floor plate, FoxA2 is a Shh target gene and the FoxA2
enhancer contains a Gli-binding site.45 Our experiment indicates
that in thymocytes, Hh signaling maintains FoxA2 expression
during pre-TCR signal transduction, as when Hh pathway
activation was inhibited by transgenic Gli2C2 expression,
FoxA2 was down-regulated.
Discussion
Here we show that Shh signaling, via Gli2, promotes thymocyte
development before pre-TCR signal transduction, but that Shh and
Gli2 are negative regulators of pre-TCR signal transduction and
thymocyte differentiation at the transition from DN to DP cell.
Analysis of Shh/, Gli3/, and conditional Smo-deficient
thymi18,21,22 has previously shown that Hh signaling regulates the
differentiation, survival, and proliferation of the earliest DN1 and DN2
thymocyte populations, and this analysis of thymocyte development in
Gli2-deficient embryos also demonstrated the nonredundant involve-
ment of Gli2 at this developmental stage. The transition from DN1 to
DN2 was reduced in the Gli2/ thymus, but we did not detect an
influence of Gli2 deficiency on DN1 or DN2 survival or proliferation.
This suggests that although Gli2 is an essential mediator of Shh-induced
differentiation at this developmental stage, it is not necessary for
Shh/Smo-induced survival or proliferation, and that there is redundancy
between Gli family members for these functions of Hh signaling in DN1
and DN2 thymocytes.
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Figure 7. PCR array analysis of gene transcription in
control and anti-CD3–treated Rag1/ and
Gli2C2Rag1/ thymocytes. Bars show average fold
change in gene transcription on anti-CD3 treatment,
relative to transcription in untreated samples. Values
were calculated by dividing the average gene transcrip-
tion in the treated samples (Rag1/  anti-CD3 or
Gli2C2Rag1/  anti-CD3) by the corresponding ones
from the control samples (Rag1/ or Gli2C2Rag1/).
(A,B) All genes shown exhibited statistically significant
change after anti-CD3 treatment in Rag1/ and/or
Gli2C2Rag1/ thymocytes. (A) Genes significantly up-
regulated after anti-CD3 treatment. P values for Rag1/:
Nrip1, P  .02; Tcf7, P  .06; Birc3, P  .02; Fasl,
P  .04; Nab2, P  .002; and CD5, P  .004. P values
for Gli2C2Rag1/: Nrip1, P  .005; Tcf7, P  .03; Birc3,
P  .5; Fasl, P  .4; Nab2, P  .04; and CD5, P  .02.
(B) Genes significantly down-regulated after anti-CD3
treatment. P values for Rag1/: CD25, P  .002; Tert,
P  .07; Myc, P  .01; Cdh1, P  .04; Birc1a, P  .05;
Brca1, P  .007; p53, P  .1; Hoxa1, P  .005; and
Wnt1, P  .03. P values for Gli2C2Rag1/: CD25,
P  .01; Tert, P  .01; Myc, P  .06; Cdh1, P  .08;
Birc1a, P  .2; Brca1, P  .04; p53, P  .04; Hoxa1,
P  .2; and Wnt1, P  .3. (C) Change in transcription of
FoxA2 after anti-CD3 treatment. Difference in change in
transcription of FoxA2 was significant between geno-
types, P  .05.
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The function of Hh signaling at the transition from DN to DP
has been controversial,1,18,22 but here we showed, using many
different mouse models, that Hh signaling negatively regulates the
pre-TCR signal for differentiation to DP cell. When Hh pathway
activation was reduced, in the Shh/Rag1/, Gli2/Rag1/,
and Gli2/ thymus, or by T lineage–specific transgenic expression
of a transcriptional-repressor form of Gli2 (Gli2C2), differentia-
tion to DP cell after pre-TCR signal transduction was increased. We
observed increased production of DP cells in the E17.5 Gli2/
thymus, and in anti-CD3–treated Shh/Rag1/, Gli2/Rag1/,
and Gli2C2Rag1/ FTOC, and in the adult Gli2C2 thymus after
depletion of the DP pool by HC treatment. In contrast, when Hh
signaling was constitutively activated in thymocytes by transgenic
expression of a constitutive transcriptional activator form of Gli2
(Gli2N2), the production of DP cells was decreased, both in
anti-CD3–treated Gli2N2Rag1/ FTOC, and in adult HC-treated
Gli2N2 thymus.
The fact that Shh/Rag1/ and Gli2/Rag1/ FTOCs both
showed increased differentiation to DP cell on anti-CD3 treatment,
whereas the Gli3/Rag1/ differentiated less efficiently,21 indi-
cated that Gli2 functions as a transcriptional activator downstream
of Shh at this developmental stage, and therefore that Gli3
functions as a transcriptional repressor.
The experiments presented here seem to conflict with a
previous analysis of a conditional T lineage–specific Smo
knockout model, which was interpreted as showing that Hh does
not influence thymocyte development after the DN2 stage.22 In
that study, Smo deficiency greatly reduced survival, prolifera-
tion, and differentiation at the DN1 to DN2 transition, resulting
in a smaller thymus with fewer DP cells than WT. However, in
vivo anti-CD3–induced differentiation of Rag2/ thymocytes
produced similar numbers of DP cells, in both conditional
Smo-deficient mice and littermates.22 Taken together, it there-
fore seems that Smo deficiency did in fact increase differentia-
tion from DN to DP stage, as the small Smo-deficient Rag2/
thymus was able to “catch up” in terms of DP production and
number with its control Rag2/ littermate thymus on transduc-
tion of the pre-TCR signal. Given that Smo is a nonredundant
component of the Hh pathway, essential for signal transduc-
tion,46 its conditional deletion should completely abrogate Hh
pathway activation in T-lineage cells. Thus, in the adult
steady-state thymus, it would have been difficult to detect the
effect of simultaneous loss of both positive and negative
regulation of T-cell development by Smo, as the profound
effects of complete loss of the earlier positive Hh signal would
mask the effects of loss of the later negative regulation of
pre-TCR–induced differentiation. By analysis of mouse mutants
in components of the signaling pathway, which are functionally
at least partially redundant (eg, redundancy between Gli pro-
teins or between Hh family members), we have been able to
detect the influence of Hh signaling at multiple stages of
development. This has also been facilitated by following
thymocyte development in situations where the transition from
DN to DP is more or less synchronized, such as on E16.5 and
E17.5 of embryonic development, in anti-CD3–treated Rag1/
FTOC, and in adult thymus as it recovers from HC depletion.
It might seem surprising that although Shh provides positive
signals for survival, differentiation, and proliferation of the
early DN thymocyte populations,18,22 it then “switches” to
function as a negative regulator of thymocyte differentiation at
later stages of thymocyte development. However, similar oppos-
ing functions for Hh signaling have been described in the
development of other tissues, such as gut and retina,47,48 and are
consistent with the action of a morphogen, which can specify
multiple cell fates. The outcome of Hh signal transduction in a
cell will depend on not only strength and duration of the signal
(determined in part by the position of the cell relative to the
source of Hh), but also the intracellular and extracellular context
of signal transduction. In the future, it will be important to
understand the context-dependent molecular machinery that
accounts for these opposing outcomes of Hh pathway activation
at different stages of thymocyte development.
The way in which Hh pathway activation in thymocytes
reduced differentiation to DP is not clear, but given that ERK
phosphorylation on CD3 ligation was reduced, it seems that Hh
pathway activation modulated the pre-TCR signal. The mechanism
of modulation remains to be investigated, and it seems likely that it
is the result of Hh-induced transcriptional changes in the develop-
ing thymocyte.
We have identified novel transcriptional targets of pre-TCR
signal transduction: genes up-regulated include the EGR1-binding
protein, Nab2, the antiapoptotic factor and caspase-inhibitor Birc3,
and the transcriptional regulator Nrip1. In addition, we found
down-regulation of genes known to be involved in thymocyte
development, such as Wnt-1, Brca-1, p53, and Myc, and genes, that
to our knowledge, have not previously been studied in thymocytes,
such as the antiapoptotic factor Birc1a, and the homeobox gene
HoxA1. Use of the Gli2C2 transgenic allowed us to look for
genes that, on pre-TCR signal transduction, are differentially
regulated by inhibition of Hh signaling in developing thymo-
cytes. Interestingly, this approach demonstrated that the physi-
ologic level of Hh signaling in thymocytes maintains expression
of FoxA2, encoding a forkhead box transcription factor and
known Hh target gene in other tissues, on pre-TCR signal
transduction. As the FoxA gene family members are regulators
of many aspects of mammalian development,49 it will be
important in the future to assess their function in thymocyte
differentiation and their potential role in differentiation to DP
cell, as a negative regulator downstream of Hh.
Acknowledgments
We thank D. Davies (Cancer Research UK) for cell sorting, C. Hui
for Gli2/ mice, and P. Beachy for the Shh/ mice.
This work was funded by Medical Research Council (MRC,
London, United Kingdom), Biotechnology and Biological Sciences
Research Council (BBSRC, Swindon, United Kingdom), Well-
come Trust (London, United Kingdom), and Leukaemia Research
Foundation (LRF, London, United Kingdom). N.J.R. is supported
by a Foulkes Foundation Fellowship.
Authorship
Contribution: N.J.R. and T.C. designed research and wrote the
paper; N.J.R., A.L.H.-T., and T.C. performed research, collected,
analyzed,and interpreted data, and performed statistical analysis;
and A.L.F., S.E.R., S.V.O., and J.T.D. performed research.
Conflict-of-interest disclosure: The authors declare no compet-
ing financial interests.
Correspondence: Tessa Crompton, Immunobiology Unit, UCL
Institute of Child Health, 30 Guilford St, London WC1N 1EH,
United Kingdom; e-mail: t.crompton@ich.ucl.ac.uk.
Shh SIGNALING INHIBITS PRE-TCR SIGNALING 5155BLOOD, 21 MAY 2009  VOLUME 113, NUMBER 21
For personal use only.on August 22, 2019. by guest  www.bloodjournal.orgFrom 
References
1. Crompton T, Outram SV, Hager-Theodorides AL.
Sonic hedgehog signalling in T-cell development
and activation. Nat Rev Immunol. 2007;7:726-
735.
2. Ingham PW, Placzek M. Orchestrating ontogen-
esis: variations on a theme by sonic hedgehog.
Nat Rev Genet. 2006;7:841-850.
3. Ingham PW, McMahon AP. Hedgehog signaling in
animal development: paradigms and principles.
Genes Dev. 2001;15:3059-3087.
4. Jia J, Jiang J. Decoding the Hedgehog signal in
animal development. Cell Mol Life Sci. 2006;63:
1249-1265.
5. Bhardwaj G, Murdoch B, Wu D, et al. Sonic
hedgehog induces the proliferation of primitive
human hematopoietic cells via BMP regulation.
Nat Immunol. 2001;2:172-180.
6. Outram SV, Varas A, Pepicelli CV, Crompton T.
Hedgehog signaling regulates differentiation from
double-negative to double-positive thymocyte.
Immunity. 2000;13:187-197.
7. Hooper JE, Scott MP. Communicating with
Hedgehogs. Nat Rev Mol Cell Biol. 2005;6:306-
317.
8. Lum L, Beachy PA. The Hedgehog response net-
work: sensors, switches, and routers. Science.
2004;304:1755-1759.
9. Koebernick K, Pieler T. Gli-type zinc finger pro-
teins as bipotential transducers of Hedgehog sig-
naling. Differentiation. 2002;70:69-76.
10. Matise MP, Joyner AL. Gli genes in development
and cancer. Oncogene. 1999;18:7852-7859.
11. Park HL, Bai C, Platt KA, et al. Mouse Gli1 mu-
tants are viable but have defects in SHH signaling
in combination with a Gli2 mutation. Develop-
ment. 2000;127:1593-1605.
12. Aza-Blanc P, Lin HY, Ruiz i Altaba A, Kornberg
TB. Expression of the vertebrate Gli proteins in
Drosophila reveals a distribution of activator and
repressor activities. Development. 2000;127:
4293-4301.
13. Sasaki H, Nishizaki Y, Hui C, Nakafuku M,
Kondoh H. Regulation of Gli2 and Gli3 activities
by an amino-terminal repression domain: implica-
tion of Gli2 and Gli3 as primary mediators of Shh
signaling. Development. 1999;126:3915-3924.
14. Mo R, Freer AM, Zinyk DL, et al. Specific and re-
dundant functions of Gli2 and Gli3 zinc finger
genes in skeletal patterning and development.
Development. 1997;124:113-123.
15. Bai CB, Auerbach W, Lee JS, Stephen D, Joyner
AL. Gli2, but not Gli1, is required for initial Shh
signaling and ectopic activation of the Shh path-
way. Development. 2002;129:4753-4761.
16. Wang B, Fallon JF, Beachy PA. Hedgehog-
regulated processing of Gli3 produces an ante-
rior/posterior repressor gradient in the developing
vertebrate limb. Cell. 2000;100:423-434.
17. Aifantis I, Mandal M, Sawai K, Ferrando A,
Vilimas T. Regulation of T-cell progenitor survival
and cell-cycle entry by the pre-T-cell receptor.
Immunol Rev. 2006;209:159-169.
18. Shah DK, Hager-Theodorides AL, Outram SV,
Ross SE, Varas A, Crompton T. Reduced thymo-
cyte development in sonic hedgehog knockout
embryos. J Immunol. 2004;172:2296-2306.
19. Sacedo´n R, Varas A, Hernandez-Lopez C, et al.
Expression of hedgehog proteins in the human
thymus. J Histochem Cytochem. 2003;51:1557-
1566.
20. Rowbotham NJ, Hager-Theodorides AL,
Cebecauer M, et al. Activation of the Hedgehog
signaling pathway in T lineage cells inhibits TCR
repertoire selection in the thymus and peripheral
T cell activation. Blood. 2007;109:3757-3766.
21. Hager-Theodorides AL, Dessens JT, Outram SV,
Crompton T. The transcription factor Gli3 regu-
lates differentiation of fetal CD4- CD8- double-
negative thymocytes. Blood. 2005;106:1296-
1304.
22. El Andaloussi A, Graves S, Meng F, Mandal M,
Mashayekhi M, Aifantis I. Hedgehog signaling
controls thymocyte progenitor homeostasis and
differentiation in the thymus. Nat Immunol. 2006;
7:418-426.
23. Outram SV, Hager-Theodorides AL, Shah DK, et
al. Indian hedgehog (Ihh) both promotes and re-
stricts thymocyte differentiation. Blood. 2009;113:
2217-2228.
24. Gutie´rrez-Frías C, Sacedon R, Hernandez-Lopez
C, et al. Sonic hedgehog regulates early human
thymocyte differentiation by counteracting the
IL-7-induced development of CD34 precursor
cells. J Immunol. 2004;173:5046-5053.
25. Chiang C, Litingtung Y, Lee E, et al. Cyclopia and
defective axial patterning in mice lacking Sonic
hedgehog gene function. Nature. 1996;383:407-
413.
26. Rowbotham NJ, Furmanski AL, Hager-Theodorides
AL, et al. Repression of hedgehog signal trans-
duction in T-lineage cells increases TCR-induced
activation and proliferation. Cell Cycle. 2008;7:
904-908.
27. Hager-Theodorides AL, Rowbotham NJ, Outram
SV, Dessens JT, Crompton T. Beta-selection:
abundance of TCRbeta-/gammadelta- CD44-
CD25- (DN4) cells in the foetal thymus. Eur J Im-
munol. 2007;37:487-500.
28. Gounari F, Chang R, Cowan J, et al. Loss of ad-
enomatous polyposis coli gene function disrupts
thymic development. Nat Immunol. 2005;6:800-
809.
29. Costello PS, Nicolas RH, Watanabe Y, Rosewell
I, Treisman R. Ternary complex factor SAP-1 is
required for Erk-mediated thymocyte positive se-
lection. Nat Immunol. 2004;5:289-298.
30. Rodewald HR, Awad K, Moingeon P, et al. Fc
gamma RII/III and CD2 expression mark distinct
subpopulations of immature CD4-CD8- murine
thymocytes: in vivo developmental kinetics and T
cell receptor beta chain rearrangement status. J
Exp Med. 1993;177:1079-1092.
31. Sasada T, Reinherz EL. A critical role for CD2 in
both thymic selection events and mature T cell
function. J Immunol. 2001;166:2394-2403.
32. Chaffin KE, Beals CR, Wilkie TM, Forbush KA,
Simon MI, Perlmutter RM. Dissection of thymo-
cyte signaling pathways by in vivo expression of
pertussis toxin ADP-ribosyltransferase. EMBO J.
1990;9:3821-3829.
33. Crompton T, Ohashi P, Schneider SD, Pircher H,
MacDonald HR. A cortisone sensitive CD3low
subset of CD4CD8- thymocytes represents an
intermediate stage in intrathymic repertoire selec-
tion. Int Immunol. 1992;4:153-161.
34. Mombaerts P, Iacomini J, Johnson RS, Herrup K,
Tonegawa S, Papaioannou VE. RAG-1-deficient
mice have no mature B and T lymphocytes. Cell.
1992;68:869-877.
35. Levelt CN, Mombaerts P, Iglesias A, Tonegawa S,
Eichmann K. Restoration of early thymocyte dif-
ferentiation in T-cell receptor beta-chain-deficient
mutant mice by transmembrane signaling through
CD3 epsilon. Proc Natl Acad Sci U S A. 1993;90:
11401-11405.
36. Azzam HS, DeJarnette JB, Huang K, et al. Fine
tuning of TCR signaling by CD5. J Immunol.
2001;166:5464-5472.
37. Goux D, Coudert JD, Maurice D, et al. Cooperat-
ing pre-T-cell receptor and TCF-1-dependent sig-
nals ensure thymocyte survival. Blood. 2005;106:
1726-1733.
38. Koltsova EK, Ciofani M, Benezra R, et al. Early
growth response 1 and NF-ATc1 act in concert to
promote thymocyte development beyond the
beta-selection checkpoint. J Immunol. 2007;179:
4694-4703.
39. Carleton M, Haks MC, Smeele SA, et al. Early
growth response transcription factors are re-
quired for development of CD4(-)CD8(-) thymo-
cytes to the CD4()CD8() stage. J Immunol.
2002;168:1649-1658.
40. Jiang D, Lenardo MJ, Zuniga-Pflucker JC. p53
prevents maturation to the CD4CD8 stage of
thymocyte differentiation in the absence of T cell
receptor rearrangement. J Exp Med. 1996;183:
1923-1928.
41. Mulroy T, McMahon JA, Burakoff SJ, McMahon
AP, Sen J. Wnt-1 and Wnt-4 regulate thymic cel-
lularity. Eur J Immunol. 2002;32:967-971.
42. Mak TW, Hakem A, McPherson JP, et al. Brcal
required for T cell lineage development but not
TCR loci rearrangement. Nat Immunol. 2000;1:
77-82.
43. Ang SL, Rossant J. HNF-3 beta is essential for
node and notochord formation in mouse develop-
ment. Cell. 1994;78:561-574.
44. Weinstein DC, Ruiz i Altaba A, Chen WS, et al.
The winged-helix transcription factor HNF-3 beta
is required for notochord development in the
mouse embryo. Cell. 1994;78:575-588.
45. Sasaki H, Hui C, Nakafuku M, Kondoh H. A bind-
ing site for Gli proteins is essential for HNF-3beta
floor plate enhancer activity in transgenics and
can respond to Shh in vitro. Development. 1997;
124:1313-1322.
46. Zhang XM, Ramalho-Santos M, McMahon AP.
Smoothened mutants reveal redundant roles for
Shh and Ihh signaling including regulation of L/R
asymmetry by the mouse node. Cell. 2001;105:
781-792.
47. Agathocleous M, Locker M, Harris WA, Perron M.
A general role of hedgehog in the regulation of
proliferation. Cell Cycle. 2007;6:156-159.
48. Neumann CJ. Hedgehogs as negative regulators
of the cell cycle. Cell Cycle. 2005;4:1139-1140.
49. Friedman JR, Kaestner KH. The Foxa family of
transcription factors in development and metabo-
lism. Cell Mol Life Sci. 2006;63:2317-2328.
5156 ROWBOTHAM et al BLOOD, 21 MAY 2009  VOLUME 113, NUMBER 21
For personal use only.on August 22, 2019. by guest  www.bloodjournal.orgFrom 
online March 9, 2009
 originally publisheddoi:10.1182/blood-2008-10-185751
2009 113: 5144-5156
 
 
Outram, Johannes T. Dessens and Tessa Crompton
Nicola J. Rowbotham, Ariadne L. Hager-Theodorides, Anna L. Furmanski, Susan E. Ross, Susan V.
 
by a Gli2-dependent mechanism
induced differentiation−Sonic hedgehog negatively regulates pre-TCR
 
http://www.bloodjournal.org/content/113/21/5144.full.html
Updated information and services can be found at:
 (5701 articles)Immunobiology and Immunotherapy    
Articles on similar topics can be found in the following Blood collections
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints
Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml
Information about subscriptions and ASH membership may be found online at:
  
Copyright 2011 by The American Society of Hematology; all rights reserved.
of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society
For personal use only.on August 22, 2019. by guest  www.bloodjournal.orgFrom 
